TikTok trans guy on testosterone and hair loss, fact-checked
Quick answer
This creator is a trans man approximately 18 months into testosterone therapy who is experiencing rapid-onset androgenic alopecia affecting both the temporal region and vertex, consistent with DHT-sensitive follicle response to exogenous androgen exposure. He references a folk genetics model around X-linked inheritance of baldness risk, which has partial but incomplete scientific support given the polygenic nature of androgenic alopecia. No treatment was discussed; this was primarily an emotional processing video, not a medical advice post.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @leandermilonoah actually say?
He described noticing rapid temple and crown hair loss less than 18 months into testosterone therapy, starting at age 29. He shared two specific beliefs: first, that starting T late might delay androgenic alopecia by mimicking a delayed puberty. Second, that trans men with two X chromosomes inherit hair loss risk from both parents, not just the maternal line. He was open about the emotional weight of this, not making medical claims, but the biology he cited is worth examining closely.
Does the science back this up?
Partly, yes. The rapid onset he describes is real and documented. The genetics claim he picked up from a TikTok video is more complicated than he was told, but the core idea is not wrong.
Androgenic alopecia in trans men on testosterone is well-documented. A 2021 study by Giltay and Gooren in the Journal of Clinical Endocrinology and Metabolism found that exogenous testosterone significantly accelerates androgenic alopecia in genetically predisposed individuals. The timeline can be compressed relative to cisgender male-pattern baldness because testosterone levels rise sharply from a near-zero baseline, rather than increasing gradually through adolescence.
On genetics: the androgen receptor gene, which is the primary driver of follicle sensitivity to dihydrotestosterone (DHT), sits on the X chromosome. That part is accurate. But baldness is polygenic. A 2017 genome-wide association study by Hagenaars et al. in PLOS Genetics identified 287 independent genetic signals associated with male-pattern baldness, spread across multiple chromosomes including autosomes. So while the X-linked androgen receptor is a major player, paternal genes on other chromosomes also contribute meaningfully to risk.
What did they get wrong (or right)?
The "trick your body into thinking you're 13" idea is understandable as a coping mechanism but scientifically off. The body does not experience a gradual adolescent androgen ramp-up when T is introduced therapeutically as an adult. Injections or gels produce adult-level androgen concentrations quickly. Follicles that are genetically sensitive to DHT respond accordingly, regardless of chronological age at the start of HRT.
The claim that trans men "get hair loss from both sides" because they have two X chromosomes is a simplification, but not entirely wrong. A trans man inherits one X from each parent. If the androgen receptor variant on the maternal X is the more penetrant one, that has historically been the main predictor. But paternal X also carries an androgen receptor allele, and autosomal contributions from the paternal line are real. Saying "both sides matter" is more accurate than the old folk rule of "look at your mom's brothers." He got the conclusion roughly right even if the mechanism he was given was oversimplified.
He was right to be skeptical of the idea that late-onset HRT offers hair-protective benefits. There is no clinical evidence supporting that hypothesis.
What should you actually know?
If you are a trans man on testosterone and concerned about hair loss, there are evidence-based options. Finasteride and dutasteride inhibit DHT conversion and are used to slow androgenic alopecia. A 2019 review by Irwig in Dermatologic Therapy noted finasteride use in trans men on T, though data specific to this population remains limited. Minoxidil (topical) is another option with a reasonable evidence base for androgenic alopecia regardless of sex assigned at birth.
The important clinical note: these interventions should be discussed with a prescribing clinician who knows your hormone levels and full health history. DHT inhibitors affect hormone metabolism and carry their own side effect profiles. Self-treating based on TikTok biology is not the move here.
The emotional reality he describes, grieving hair loss faster than expected, is valid and common. Connecting with others going through the same thing, which is what he was actually trying to do, is not bad advice at all.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For TikTok trans guy on testosterone and hair loss, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
The human peptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging
Anchor review for copper peptide gene-expression and tissue-repair claims.
PubMed
Effects of glycyl-histidyl-lysine-Cu on wound healing
Search-backed PubMed trail for wound-healing claims where specific topical versus injectable context matters.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
TikTok trans guy on testosterone and hair loss, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
This creator is a trans man approximately 18 months into testosterone therapy who is experiencing rapid-onset androgenic alopecia affecting both the temporal region and vertex, consistent with DHT-sensitive follicle response to exogenous androgen exposure.
FormBlends verdict
This creator is a trans man approximately 18 months into testosterone therapy who is experiencing rapid-onset androgenic alopecia affecting both the temporal region and vertex, consistent with DHT-sensitive follicle response to exogenous androgen exposure. He references a folk genetics model around X-linked inheritance of baldness risk, which has partial but incomplete scientific support given the polygenic nature of androgenic alopecia. No treatment was discussed; this was primarily an emotional processing video, not a medical advice post.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This creator is a trans man approximately 18 months into testosterone therapy who is experiencing rapid-onset androgenic alopecia affecting both the temporal region and vertex, consistent with DHT-sensitive follicle response to exogenous androgen exposure. He references a folk genetics model around X-linked inheritance of baldness risk, which has partial but incomplete scientific support given the polygenic nature of androgenic alopecia. No treatment was discussed; this was primarily an emotional processing video, not a medical advice post.
- Androgenic alopecia can onset within the first 1-2 years of testosterone therapy in trans men, as exogenous T drives a rapid shift in androgen exposure rather than a gradual adolescent ramp-up.
- The 'look at your mom's brothers' rule for predicting baldness is outdated. A 2017 GWAS (Hagenaars et al., PLOS Genetics) identified 287 genetic loci linked to male-pattern baldness, many of them autosomal and inherited from either parent.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Androgenic alopecia can onset within the first 1-2 years of testosterone therapy in trans men, as exogenous T drives a rapid shift in androgen exposure rather than a gradual adolescent ramp-up.
- The 'look at your mom's brothers' rule for predicting baldness is outdated. A 2017 GWAS (Hagenaars et al., PLOS Genetics) identified 287 genetic loci linked to male-pattern baldness, many of them autosomal and inherited from either parent.
- The androgen receptor gene is X-linked, so both X chromosomes in a trans man (one from each parent) carry relevant variants, making paternal-line baldness a legitimate risk factor alongside maternal.
- Starting testosterone therapy later in life does not appear to delay or reduce the risk of androgenic alopecia. No clinical evidence supports that hypothesis.
- Evidence-based treatment options for androgenic alopecia in trans men include finasteride, dutasteride, and topical minoxidil, but these carry their own side effect profiles and require discussion with a prescribing clinician familiar with your hormone regimen.
- A 2019 review by Irwig in Dermatologic Therapy noted use of 5-alpha reductase inhibitors in trans men on testosterone, though robust population-specific trial data remains limited.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
[ˈleːan] (he/him) · TikTok creator
7.3K views on this video
Talking hair loss as a trans guy EDIT: I know not all parents are dad's and mom's, I'm sorry for generalising! #trans #transguy #testosterone #hrt #hairloss
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by [ˈleːan] (he/him), not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.